Based on pivotal trials, it was licensed in Japan for metastatic HER2‐positive breast cancer (BC) in 20013 and for metastatic HER2‐positive gastric cancer (GC) in 2011.4 This evidence concerns the gene ERBB2 and breast carcinoma.